What’s Next for Syros Pharmaceuticals, Inc. (SYRS) After Forming Bearish Double Bottom Pattern?

August 9, 2018 - By Ash Maslow

The chart of Syros Pharmaceuticals, Inc. (SYRS) shows a double bottom with $10.84 target or 6.00 % below today’s $11.53 share price. The 5 months chart pattern indicates high risk for the $388.04 million company. It was reported on Aug, 9 by Finviz.com. If the $10.84 price target is reached, the company will be worth $23.28 million less. Double bottoms are rare but powerful chart patterns.

The stock decreased 0.35% or $0.04 during the last trading session, reaching $11.53. About 80,863 shares traded. Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) has declined 14.15% since August 9, 2017 and is downtrending. It has underperformed by 26.72% the S&P500.

More notable recent Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) news were published by: Benzinga.com which released: “The Daily Biotech Pulse: FDA Snub For Gemphire, Ligand Earnings, Insmed’s Antibiotic Faces FDA Panel” on August 07, 2018, also Businesswire.com with their article: “Syros Reports Second Quarter 2018 Financial Results and Highlights Key Accomplishments and Upcoming Milestones” published on August 07, 2018, Businesswire.com published: “Syros to Present at 2018 Wedbush PacGrow Healthcare Conference” on August 08, 2018. More interesting news about Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) were released by: Benzinga.com and their article: “77 Biggest Movers From Yesterday” published on August 08, 2018 as well as Nasdaq.com‘s news article titled: “Investor Expectations to Drive Momentum within ShotSpotter, Kohl’s, Cheniere Energy Partners LP, Palo Alto Networks …” with publication date: July 26, 2018.

Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing treatments for cancer and immune-mediated diseases, and building a pipeline of gene control medicines. The company has market cap of $388.04 million. The Company’s lead drug candidates are SY-1425, a selective RARa agonist in a Phase 2 clinical trial for genomically defined subsets of patients with acute myeloid leukemia and myelodysplastic syndrome; and SY-1365, a selective CDK7 inhibitor with potential in a range of solid tumors and blood cancers. It currently has negative earnings. The firm was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.